Response and effectiveness

Entyvio may lessen some ulcerative colitis (UC) symptoms within a few weeks, but it could take up to six weeks to start noticing a difference. Entyvio can significantly reduce symptoms, bring about remission, and reduce or eliminate the need for corticosteroids with continued use. Symptoms like cramping and pain in the stomach, diarrhea, and fatigue disappear when a person is in remission.

In one trial, 46% (225 patients) of 373 patients with UC who received Entyvio had a clinical response at 6 weeks, compared to 26% (149 patients) who received a placebo (inactive agent). At 6 weeks, some patients achieved clinical remission (17% on Entyvio vs. 5% on placebo). In one-year studies, 42% of patients were in clinical remission at Week 52, compared to 16% of patients on a placebo.

In two Entyvio studies that were extended to a year, 39% and 44% of patients were in remission at the end of the trial, compared to 22% and 30% of placebo patients. Both studies yielded statistically significant results.

In 2 studies, 15% of Crohn's disease patients receiving Entyvio were in remission at 6 weeks, compared to 7% and 12% of patients receiving placebo. It was determined that only one study was statistically significant.

Each patient has a unique response to medication therapy and a range of disease severity. Entyvio won't work on all patients.

Your doctor may think about stopping your Entyvio treatment if, after 14 weeks, you have not noticed a therapeutic benefit from it.